<正>Objective:To evaluate the efficacy and safety in patients with hepatocellular carcinoma treated with sorafenib and determine the predictive factors for survival.Methods:From April 2009 to December 2010

all patients with hepatocellular carcinoma treated with sorafenib were included in the study.Clinical data and survival time were collected.Survival analysis was conducted using the Kaplan-Meier method

and predictive factors for survival were analysed using the Cox’s model.Results:A total of 51 patients were included in the study

the median time of follow-up was 10 months（range 1-22）.All the 51 patients had one or more adverse events

of which 2 patients died of upper gastrointestinal bleeding and 6 patients discontinued treatment.The mean survival time was 11 months and 1-year survival was 60.8%.On univariate analysis

the median survival time of patients with tumors of BCLC A

B and C were 17

12.5 and 8.5 months

and 1-year survival were 71.4%

61.1%

and 23.1%

respectively（P=0.006）.Compared with those with mild and poor arterial supply tumors

patients with good arterial supply tumors had longer median survival time（12 months vs 8 months and 9 months） and higher 1-year survival（52.0%vs 30.8%and 38.5%）（P=0.037）.Patients with portal invasion had shorter median survival time and lower 1-year survival（8.5 months vs 13 months and 57.6%vs 16.7%

respectively） than those without（P=0.012）.Patients with prealbumin≥170 mg/L had longer median survival time and higher 1-year survival（13.5 months vs 9 months and 55.6%vs 36.4%

respectively） than those with prealbumin<170 mg/L（P=0.016）.Early tumor BCLC staging and high level of prealbumin were independent predictive factors for survival on multivariate analysis using Cox’s regression model

the hazard ratio were 3.69（95%CI:1.30-10.53

P=0.015） and 3.53（95%CI:1.40-8.91

P=0.008） respectively.Conclusion:Upper gastrointestinal bleeding was a severe event need to be concerned in patients with hepatocellular carcinoma treated with sorafenib.Patients with high level of prealbumin could benefit more from sorafenib treatment

and prealbumin could be a predictor for survival in HCC patients treated with sorafenib.